Evolent Health Financials - Benzinga

Evolent Health Inc

EVHNYSE

Trade with Public

Trade with Public

$4.74

0.040.85%

At close: Aug 20, 5:00 PM EST

$4.74

0.040.85%

Pre-Market: 6:31 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Evolent Health Financials

Evolent Health (EVH) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Evolent Health Raises FY2026 Sales Guidance from $2.400B-$2.600B to $2.600B-$2.700B vs $2.503B Est

Evolent Health (NYSE:EVH) raises FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.600 billion-$2.700 billion vs $2.503 billion estimate.

Benzinga Newsdesk

PRO
Evolent Health Q2 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $652.520M Beat $597.997M Estimate

Evolent Health (NYSE:EVH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 120 percent increase over losses of $(0.10) per share from the same

Benzinga Newsdesk

PRO
Evolent Health Affirms FY2026 Sales Guidance of $2.400B-$2.600B vs $2.487B Est.

Evolent Health (NYSE:EVH) affirms FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.400 billion-$2.600 billion vs $2.487 billion estimate.

Benzinga Newsdesk

PRO
Evolent Health Q1 Adj. EPS $(0.02) Beats $(0.05) Estimate, Sales $496.246M Miss $534.669M Estimate.

Evolent Health (NYSE:EVH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 133.33 percent decrease over earnings of $0.06 per share from the

Benzinga Newsdesk

PRO
Evolent Health Sees FY2026 Sales $2.400B-$2.600B vs $2.379B Est

Evolent Health (NYSE:EVH) sees FY2026 sales of $2.400 billion-$2.600 billion vs $2.379 billion analyst estimate.

Benzinga Newsdesk

PRO
Evolent Health Q4 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $468.719M Beat $468.701M Estimate

Evolent Health (NYSE:EVH) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 37.93 percent. This is a 500 percent increase over losses of $(0.02) per share from the same

Benzinga Newsdesk